Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
Source: View publication →
The VALUE trial demonstrated that a valsartan-based regimen and an amlodipine-based regimen provided similar protection against major cardiac morbidity and mortality in high-risk hypertensive patients, despite the amlodipine-based regimen achieving more effective blood pressure control, particularly during the early phase of treatment.
Key Findings
Study Design
Study Limitations
Clinical Significance
The trial highlights the paramount clinical importance of rapid blood pressure control in high-risk patients, suggesting that the speed and magnitude of blood pressure reduction may be more critical for preventing cardiac events than the specific choice between an ARB and a long-acting CCB. Furthermore, it identified potential metabolic differences, specifically the lower rate of new-onset diabetes with ARB therapy, which informs personalized antihypertensive selection.
Historical Context
Designed in 1997, the VALUE trial was one of the largest cardiovascular outcome trials for the ARB class. It sought to determine if valsartan offered 'beyond-blood-pressure' protection compared to amlodipine. The results notably underscored that failing to achieve prompt blood pressure targets can limit the assessment of cardiovascular benefit in clinical trials.
Guided Discussion
High-yield insights from every perspective
The VALUE trial compared valsartan (an ARB) to amlodipine (a CCB). From a physiological standpoint, how do these two drug classes differ in their effect on the Renin-Angiotensin-Aldosterone System (RAAS) and peripheral vascular resistance?
Key Response
Students must understand that ARBs selectively block the AT1 receptor, inhibiting the vasoconstrictive and pro-fibrotic effects of Angiotensin II, while CCBs like amlodipine cause direct vasodilation by inhibiting L-type calcium channels in vascular smooth muscle. The trial hypothesized that ARBs might provide 'pleiotropic' cardiac protection beyond simple blood pressure reduction through RAAS modulation.
In the VALUE trial, the amlodipine-based regimen achieved blood pressure control significantly faster and more effectively in the first six months than the valsartan-based regimen. How should this 'early BP gap' influence your choice of initial therapy for a patient with high cardiovascular risk?
Key Response
The trial demonstrated that early differences in BP control (especially in the first 3-6 months) correlated with a significantly lower risk of stroke and myocardial infarction in the amlodipine group. For residents, the clinical takeaway is that the 'power' and 'speed' of a BP medication are critical for high-risk patients; simply choosing the right class is insufficient if target goals are not met rapidly.
Despite similar primary composite outcomes, valsartan showed a significant reduction in new-onset diabetes compared to amlodipine. How does this finding integrate with the results of the NAVIGATOR trial when managing a hypertensive patient with impaired glucose tolerance?
Key Response
Fellows should recognize the metabolic benefits of RAAS inhibitors. While VALUE showed valsartan reduced new-onset diabetes risk, NAVIGATOR showed that while valsartan reduced the progression to diabetes, it did not necessarily reduce cardiovascular events in that specific pre-diabetic population. This requires a nuanced balance between metabolic preservation and immediate hemodynamic protection.
The VALUE trial is often cited as evidence that 'blood pressure lowering itself' is more important than the specific drug class used. Given the 'legacy effect' observed when the groups eventually achieved BP parity, do you believe the early failure to achieve BP control in the valsartan arm created an irreversible 'cardiovascular debt'?
Key Response
This question addresses the concept that early uncontrolled hypertension causes vascular damage that later optimization cannot fully undo. The fact that valsartan-treated patients never fully 'caught up' in terms of event reduction despite later BP equilibration suggests that the window for maximal protection is during the initial phase of treatment, reinforcing the need for aggressive early titration.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Analyze the impact of the 'forced titration' design used in VALUE. How does a fixed-dose escalation protocol potentially confound the comparison of drug-specific pleiotropic effects when the drugs possess unequal dose-response potencies?
Key Response
Researchers must account for the fact that if the starting doses (e.g., 80mg valsartan vs 5mg amlodipine) are not biologically equipotent in BP lowering, the trial results will be driven by the degree of pressure reduction rather than the biochemical mechanisms of the molecules. The PhD perspective critiques whether the study was a fair 'head-to-head' of mechanisms or merely a comparison of two different BP-lowering trajectories.
The primary outcome of VALUE was neutral (no significant difference in cardiac morbidity/mortality), yet the amlodipine arm was superior in several secondary endpoints like stroke. As an editor, would you require the authors to soften the 'comparability' conclusion in the abstract given the significant early BP disparity between groups?
Key Response
Editors look for 'spin.' If a trial fails its primary endpoint but shows differences in secondary outcomes due to a failure to maintain experimental control (the BP gap), the claim of 'equivalence' can be misleading. A rigorous reviewer would flag that the neutrality of the primary endpoint might be a type II error caused by the superior BP control in the amlodipine arm masking a potential benefit of valsartan.
Current ACC/AHA guidelines place ARBs and CCBs as equally valid first-line options for hypertension. Based on the VALUE findings regarding stroke prevention and the speed of BP reduction, is there sufficient evidence to prioritize CCBs over ARBs in patients whose primary risk factor is cerebrovascular disease?
Key Response
Guideline committees must weigh the strength of evidence (Level A in VALUE) against existing recommendations. While the 2017 ACC/AHA guidelines do not prioritize one over the other, the VALUE data—combined with ASCOT-BPLA—suggests CCBs may have a more robust profile for stroke prevention and rapid control, whereas RAAS inhibitors remain prioritized for patients with heart failure (HFrEF) or proteinuric kidney disease.
Clinical Landscape
Noteworthy Related Trials
ALLHAT Trial
Tested
Chlorthalidone
Population
Patients aged 55+ with hypertension and at least one additional CV risk factor
Comparator
Amlodipine or Lisinopril
Endpoint
Fatal coronary heart disease or nonfatal myocardial infarction
ASCOT-BPLA Trial
Tested
Amlodipine (+/- Perindopril)
Population
Hypertensive patients with at least three CV risk factors
Comparator
Atenolol (+/- Bendroflumethiazide)
Endpoint
Nonfatal myocardial infarction and fatal coronary heart disease
ONTARGET Trial
Tested
Telmisartan
Population
Patients 55+ with established vascular disease or high-risk diabetes
Comparator
Ramipril
Endpoint
Composite of CV death, MI, stroke, or hospitalization for heart failure
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis